$3.670
+0.339 (+9.23%)At close
CTMX News
CTMX Events
CytomX Therapeutics' Varseta-M Receives FDA Fast Track Designation
CytomX Therapeutics announced that the FDA has granted Fast Track Designation to Varseta-M for the treatment of patients with relapsed/refractory metastatic colorectal cancer. Varseta-M is an antibody drug conjugate directed toward epithelial cell adhesion molecule with a topoisomerase-1 inhibitor payload.
CytomX Reports Q2 Revenue of $1.42M, Below Consensus
Reports Q2 revenue $1.42M, consensus $12.34M. "CytomX had a productive second quarter as we advanced and broadened the Varseta-M program, the only EpCAM-directed antibody drug conjugate (ADC) in clinical development and a potentially best-in-class ADC for colorectal cancer. As we drive Varseta-M towards its first registrational study in late-line CRC, we are also accelerating our broader vision of earlier line utilization in CRC combination regimens, while also initiating development in additional gastrointestinal cancers of high unmet need," said Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics.
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
CytomX Therapeutics announced the appointment of Alejandra Carvajal as chief legal officer. In this role, Carvajal will support the company's strategic, operational, and pipeline initiatives. Most recently, Carvajal was the senior VP, chief legal officer and secretary at Mersana Therapeutics.
CytomX Expands Collaboration Agreement with Regeneron
CytomX Therapeutics (CTMX) announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals (REGN) to create conditionally-activated bispecific cancer therapies utilizing CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform. The Regeneron and CytomX collaboration, initially entered into in 2022, is focused on applying CytomX's biologic masking strategies in combination with Regeneron's bispecific antibodies to develop investigational bispecifics that remain inactive until activated by proteases in the tumor microenvironment. Under the expanded agreement, Regeneron and CytomX will continue to collaborate on discovery activities to identify and validate conditionally active bispecific antibodies. Regeneron will be responsible for funding preclinical and clinical development and commercialization activities. CytomX will receive a target nomination payment of $37M for two additional targets that have been selected, and Regeneron has the option to select up to six additional future targets. Total potential target nomination payments, preclinical, clinical, regulatory and commercial milestones covered under the scope of the expanded collaboration could reach up to approximately $4B. CytomX is also eligible to receive tiered global net sales royalties on products covered under the collaboration.
CytomX Reports Q1 Revenue of $10.26M
Reports Q1 revenue $10.26M, consensus $4.68M. "CytomX has continued to gain tremendous momentum in 2026 and we remain highly focused on executing against the multiple layers of potential value creation we see for Varseta-M. Our top priority is to advance this highly differentiated, first in class EpCAM ADC into a registrational study in late-line CRC while also investing to unlock the broader potential of Varseta-M in earlier line CRC and other cancers," said Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.